Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Challenges in the treatment of mTNBC

Peter Schmid • 19 Oct 2018
ESMO 2018
Breast Cancer

Metastatic triple negative breast cancer (mTNBC) remains one of the most aggressive subtypes of breast cancer. In this video, Peter Schmid, MD, FRCP, PhD, of the Barts Cancer Institute, London, UK, describes the relatively poor treatment outcomes for these patients, attributing these outcomes to resistance from chemotherapy, and the heterogeneous nature of the cancer. Speaking at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Prof. Schmid further highlights the importance of implementing targeted therapies for mTNBC to improve survival outcomes.

More from Peter Schmid

lidERA: giredestrant efficacy by menopausal status in ER+/HER2- breast cancer
4:24
lidERA: giredestrant efficacy by menopausal status in ER+/HER2- breast cancer
Peter Schmid • 31 May 2026
KEYNOTE-522: final analysis of pembrolizumab and chemotherapy in TNBC
4:12
KEYNOTE-522: final analysis of pembrolizumab and chemotherapy in TNBC
Peter Schmid • 31 May 2026
KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC
5:01
KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC
Peter Schmid • 15 Sep 2024
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
4:20
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
Peter Schmid • 22 Oct 2023

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals